At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Closed 07-30 16:00:00 EDT
5.76
+0.04
+0.70%
盘后5.79
+0.03+0.52%
19:34 EDT
High5.82Low5.57Vol489.72K
Open5.69D1 Closing5.72Amplitude4.37%
Mkt Cap180.23MTradable Cap97.22MTotal Shares31.29M
T/O2.79MT/O Rate2.90%Tradable Shares16.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
GlobeNewswire  ·  04:05
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Bicycle Therapeutics is Maintained at Buy by Needham
Dow Jones  ·  03:26
Bicycle Therapeutics is Maintained at Buy by Needham
Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer
TIPRANKS  ·  01:05
Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer
Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel
TIPRANKS  ·  01:05
Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel
Travere Therapeutics is Maintained at Buy by Canaccord Genuity
Dow Jones  ·  00:05
Travere Therapeutics is Maintained at Buy by Canaccord Genuity
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
GlobeNewswire  ·  07-30 20:00
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor
TIPRANKS  ·  07-30 19:58
Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor
Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate
Benzinga Earnings  ·  07-30 19:56
Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
GlobeNewswire  ·  07-30 19:25
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Maxim Downgrades Silexion Therapeutics to Hold From Buy
MT Newswires Live  ·  07-30 19:15
Maxim Downgrades Silexion Therapeutics to Hold From Buy
Bicycle Therapeutics reports Q2 EPS (72c), consensus (58c)
TIPRANKS  ·  07-30 19:12
Bicycle Therapeutics reports Q2 EPS (72c), consensus (58c)
Bicycle Therapeutics sees cash runway into 2030
TIPRANKS  ·  07-30 19:11
Bicycle Therapeutics sees cash runway into 2030
Qyuns Therapeutics Partner Caldera to Merge with Synlogic
MT Newswires Live  ·  07-30 11:32
Qyuns Therapeutics Partner Caldera to Merge with Synlogic
Major Insider Move Signals Growing Confidence in Outlook Therapeutics
TIPRANKS  ·  07-30 10:05
Major Insider Move Signals Growing Confidence in Outlook Therapeutics
Quince Therapeutics Initiated at Outperform by Oppenheimer
Dow Jones  ·  07-30 00:34
Quince Therapeutics Initiated at Outperform by Oppenheimer
Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating
MT Newswires Live  ·  07-29 22:34
Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating
Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program
GlobeNewswire  ·  07-29 20:30
Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
GlobeNewswire  ·  07-29 20:30
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Processa Pharmaceuticals acquires Vidya Therapeutics in stock-for-stock deal
TIPRANKS  ·  07-29 19:57
Processa Pharmaceuticals acquires Vidya Therapeutics in stock-for-stock deal
Quince Therapeutics initiated with an Outperform at Oppenheimer
TIPRANKS  ·  07-29 19:35
Quince Therapeutics initiated with an Outperform at Oppenheimer

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--